{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:31:50Z","timestamp":1768879910550,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1245\/s10434-016-5534-3","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T18:19:17Z","timestamp":1476209957000},"page":"823-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy"],"prefix":"10.1245","volume":"24","author":[{"given":"Takashi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Yanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Komai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Murota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"5534_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","volume":"174","author":"JE Rosenberg","year":"2005","unstructured":"Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14\u201320.","journal-title":"J Urol."},{"key":"5534_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jjco\/hyh005","volume":"34","author":"A Takahashi","year":"2004","unstructured":"Takahashi A, Tsukamoto T, Tobisu K, et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn J Clin Oncol. 2004;34:14\u20139.","journal-title":"Jpn J Clin Oncol."},{"key":"5534_CR3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","volume":"65","author":"JA Witjes","year":"2014","unstructured":"Witjes JA, Comp\u00e9rat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778\u201392.","journal-title":"Eur Urol."},{"key":"5534_CR4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/bjc.2011.399","volume":"105","author":"N Tanaka","year":"2011","unstructured":"Tanaka N, Miyajima A, Kosaka T, et al. Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer. Br J Cancer. 2011;105:1331\u20137.","journal-title":"Br J Cancer."},{"key":"5534_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/13543784.2015.1041588","volume":"24","author":"CR Mazzola","year":"2015","unstructured":"Mazzola CR, Chin J. Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin Investig Drugs. 2015;24:913\u201327.","journal-title":"Expert Opin Investig Drugs."},{"key":"5534_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clgc.2013.05.005","volume":"11","author":"R Pili","year":"2013","unstructured":"Pili R, Qin R, Flynn PJ, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11:477\u201383.","journal-title":"Clin Genitourin Cancer."},{"key":"5534_CR7","doi-asserted-by":"crossref","unstructured":"Shirotake S, Miyajima A, Kosaka T, et al. Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology. 2011;77:1009.e1019\u201325.","DOI":"10.1016\/j.urology.2010.11.002"},{"key":"5534_CR8","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/1535-7163.MCT-10-0535","volume":"9","author":"N Tanaka","year":"2010","unstructured":"Tanaka N, Miyajima A, Kosaka T, et al. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol Cancer Ther. 2010;9:2982\u201392.","journal-title":"Mol Cancer Ther."},{"key":"5534_CR9","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","volume":"19","author":"K Yuge","year":"2012","unstructured":"Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012;19:3987\u201393.","journal-title":"Ann Surg Oncol."},{"key":"5534_CR10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2015.05.104","volume":"194","author":"ML Blute","year":"2015","unstructured":"Blute ML, Rushmer TJ, Shi F, et al. Renin-angiotensin inhibitors decrease recurrence after transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer. J Urol. 2015;194:1214\u20139.","journal-title":"J Urol."},{"key":"5534_CR11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.110.217737","volume":"106","author":"A Leask","year":"2010","unstructured":"Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010;106:1675\u201380.","journal-title":"Circ Res."},{"key":"5534_CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.trsl.2014.05.001","volume":"164","author":"M Cavalera","year":"2014","unstructured":"Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164:323\u201335.","journal-title":"Transl Res."},{"key":"5534_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11892-004-0055-z","volume":"4","author":"TA McGowan","year":"2004","unstructured":"McGowan TA, Zhu Y, Sharma K. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep. 2004;4:447\u201354.","journal-title":"Curr Diab Rep."},{"key":"5534_CR14","doi-asserted-by":"crossref","first-page":"752406","DOI":"10.1155\/2009\/752406","volume":"2009","author":"F Montecucco","year":"2009","unstructured":"Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediat Inflamm. 2009;2009:752406.","journal-title":"Mediat Inflamm."},{"key":"5534_CR15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.22209","volume":"225","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S. Angiotensin II\/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase\/Akt pathway. J Cell Physiol. 2010;225:168\u201373.","journal-title":"J Cell Physiol."},{"key":"5534_CR16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","volume":"22","author":"JH Neo","year":"2007","unstructured":"Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 2007;22:577\u201384.","journal-title":"J Gastroenterol Hepatol."},{"key":"5534_CR17","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.3892\/mmr.2015.3849","volume":"12","author":"H Huang","year":"2015","unstructured":"Huang H, Zhou J, Cui Z, Wang B, Hu Y. Angiotensin II type 1 receptor-associated protein plays a role in regulating the local renin-angiotensin system in HSC-T6 cells. Mol Med Rep. 2015;12:3763\u20138.","journal-title":"Mol Med Rep."},{"key":"5534_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/157488709788185996","volume":"4","author":"A Miyajima","year":"2009","unstructured":"Miyajima A, Kikuchi E, Kosaka T, Oya M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer. Rev Recent Clin Trials. 2009;4:75\u20138.","journal-title":"Rev Recent Clin Trials."},{"key":"5534_CR19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/15384047.2014.1002357","volume":"16","author":"S Ishiguro","year":"2015","unstructured":"Ishiguro S, Yoshimura K, Tsunedomi R, et al. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther. 2015;16:307\u201316.","journal-title":"Cancer Biol Ther."},{"key":"5534_CR20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/pros.22653","volume":"73","author":"MO Guimond","year":"2013","unstructured":"Guimond MO, Battista MC, Nikjouitavabi F, et al. Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer. Prostate. 2013;73:1057\u201368.","journal-title":"Prostate."},{"key":"5534_CR21","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/1078-0432.CCR-05-2213","volume":"12","author":"M Kosugi","year":"2006","unstructured":"Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006;12:2888\u201393.","journal-title":"Clin Cancer Res."},{"key":"5534_CR22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/iju.12827","volume":"22","author":"A Miyajima","year":"2015","unstructured":"Miyajima A, Kosaka T, Kikuchi E, Oya M. Renin-angiotensin system blockade: Its contribution and controversy. Int J Urol. 2015;22:721\u201330.","journal-title":"Int J Urol."},{"key":"5534_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2007.00025.x","volume":"20","author":"M Kosugi","year":"2007","unstructured":"Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell. 2007;20:1\u20139.","journal-title":"Hum Cell."},{"key":"5534_CR24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179\u201384.","journal-title":"Lancet."},{"key":"5534_CR25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","volume":"135","author":"S Wilop","year":"2009","unstructured":"Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135:1429\u201335.","journal-title":"J Cancer Res Clin Oncol."},{"key":"5534_CR26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jnci\/djn262","volume":"100","author":"JB Christian","year":"2008","unstructured":"Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, Trial V. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100:1223\u201332.","journal-title":"J Natl Cancer Inst."},{"key":"5534_CR27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","volume":"97","author":"JP Fryzek","year":"2006","unstructured":"Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat. 2006;97:231\u20136.","journal-title":"Breast Cancer Res Treat."},{"key":"5534_CR28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15:535\u201341.","journal-title":"Cancer Causes Control."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5534-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T13:11:40Z","timestamp":1568466700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5534-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["5534"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5534-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}